Taiho Oncology, Inc.
Paul Young is an experienced regulatory affairs professional currently serving as Associate Director - Regulatory Affairs Strategy at Taiho Oncology, Inc. since January 2024, previously holding the position of Senior Manager, Regulatory Affairs Strategy. Prior experience includes senior and managerial roles at Astex Pharmaceuticals, Inc. from July 2018 to January 2024, and various regulatory affairs positions at Impax Laboratories, Abbott Vascular, and JANSSEN Alzheimer Immunotherapy. Paul began the career as a Quality Assurance Specialist at Nuvelo, Inc. and has held roles with increasing responsibility in regulatory and quality assurance capacities across several organizations. Academic qualifications include a Master of Science in Regulatory Affairs from San Diego State University and a Bachelor of Science in Biochemistry, Cell and Molecular Biology from San Francisco State University.
This person is not in any teams
This person is not in any offices
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com